ated allogeneic BMT and in 40-60% of patients treated in advanced disease stages. Relapse rates of 40-60% are also In a retrospective single centre study we examined the found in patients in 1st CP when a T cell-depleted BMT outcome of five different therapy approaches in 48 has been performed. 1, 2 patients in whom a relapse of CML (13 cytogenetic The treatment of relapsed CML patients after allogeneic relapses, 35 hematological relapses: 10 chronic phase BMT often has a poor outcome. The best outcome is found (CP), nine accelerated phase, 16 blast crisis) occurred in patients with an isolated cytogenetic relapse in whom a after allogeneic BMT. Cyclosporin A (CsA) withdrawal, spontaneous partial or complete disappearance of the Philainterferon alpha-2b (IFN-␣) therapy, donor leukocyte delphia (Ph) chromosome-positive cells occurs without spetransfusions (DLT), second transplantation (2nd BMT), cific treatment. These patients have the highest survival and chemotherapy (CTX) alone were used and studied probability of 50% after 6 years, as compared to 30% of for their response rates. Patients who achieved a compatients relapsing hematologically in chronic stage and 0% plete hematologic and cytogenetic remission (CR) were of patients in advanced stage (accelerated phase (AP) or studied for BCR-ABL transcripts and for their chimerblast crisis (BC) ). Patients with CML in an advanced disism status by PCR. A strong antileukemic effect was ease stage generally do not survive more than 3.5 years observed after abrupt CsA withdrawal, with 10 of 20 after a post-transplant relapse. Furthermore, this group of patients achieving a CR (50%). All 10 patients with patients has the poorest response rate to all post-transplant early stage (nine cytogenetic and one CP), but none of therapeutic approaches.
Patients and methods
mg/kg/day × 2) and busulfan (4.0 mg/kg/day × 4) in two. One patient received busulfan (4.0 mg/kg/day for 4 days) followed by cyclophosphamide (60 mg/kg/day × 2) and Ethics thiotepa (5 mg/kg/day × 2).
Approval for this study was obtained from the Institutional Review Board on Medical Ethics at the Essen University
Definition of relapse Hospital.
Hematological relapse was diagnosed on the basis of standard hematological criteria. Cytogenetic relapse was conPatients sidered to be present if one or more Ph+ metaphases were Forty-eight patients with CML who had undergone allodetected in repeated cytogenetic analysis without evidence geneic BMT between May 1982 and December 1995 at of hematologic relapse. our institution and subsequently relapsed were studied in a retrospective analysis. Forty-four of the donor/recipient
Isolation of genomic DNA and minisatellite PCR pairs were matched at the HLA-A, B, C and DR loci and were nonreactive in mixed lymphocyte culture (MLC).
DNA was prepared from peripheral blood mononuclear Four patients received grafts from antigen-mismatched cells obtained from the donor and recipient before the transextended family donors, and four other patients were plant using the phenol/chloroform method. 27 After the grafted with marrow of unrelated donors.
transplant, DNA was extracted exclusively from the peripheral blood to allow determination of chimerism. For PCR amplification we used specific primers designed to flank Marrow transplant characteristics repeat units of the following human minisatellite regions: The conditioning regimen consisted of cyclophosphamide APO-B, 33.1, 33.6, YNZ-22 and D1S80 as previously (60 mg/kg/day × 2) preceded or followed by single-dose or described. In male patients with female donor chimerism, fractioned total body irradiation (TBI). Details of the differanalyses were performed by PCR amplification of Y ent TBI regimens used in this study have been previously chromosome-specific nucleotide sequences as previously described. 21 In short, five patients received single-dose TBI published. 28, 29 at a dose of 8. 6 Gy delivered either by a linear accelerator (two patients) or by a telecobalt source. Forty-one patients Isolation of RNA and detection of BCR/ABL fusion were treated with a fractioned TBI regimen delivered by a product telecobalt source consisting of one daily fraction of 2.5 Gy on 4 consecutive days to a cumulative dose of 10 Gy (8 RNA was prepared from peripheral blood cells, BM buffy Gy lung dose).
coat cells, and K562 cells as a positive control and One patient received busulfan (4.0 mg/kg/day for 4 days) extracted by the acid guanidium/phenol/chloroform followed by cyclophosphamide (60 mg/kg/day × 2) and method. 30 BCR-ABL transcripts were studied in a two-step another busulfan (4.0 mg/kg/day for 4 days), cyclophos-RT-PCR with nested primers as previously described. 31 phamide (60 mg/kg/day × 2), and thiotepa (5 mg/kg/ day × 2). All transplants were performed without prior ex Cytogenetics vivo removal of donor lymphocytes from the graft. Irradiated leukocyte-depleted blood products were exclusIn all patients with CML the Philadelphia translocation was ively used for blood component substitution throughout the demonstrable by bone marrow cytogenetic analysis prior post-transplant course.
to transplant. To prevent acute GVHD, five patients received singleagent intravenous (i.v.) methotrexate (MTX) according to Statistical analysis the standard Seattle regimen. 22 In 33 patients, short course MTX in conjunction with continuous i.v. CsA was used,
Comparisons between continuous covariates were perforas previously published. 23 Ten patients were treated with a med by the two-tailed Wilcoxon rank-score test across combination of a monoclonal antibody directed to a constrata. Differences between discrete covariates were comstant epitope of the alpha/beta T cell receptor and CsA, 24 pared by the two-tailed Fisher's exact test. Time to event as shown in Table 1 .
estimates (± standard errors) were calculated by the proThe assessment and grading of acute and chronic GVHD duct-limit method with right-censoring of subjects at the followed the commonly accepted clinical criteria as prolast time point at which they were at risk for a given posed by Gluckberg et al 25 and Thomas et al. 26 event. 32 Features involved in all univariate and multivariate analyses were time interval between first BMT and relapse, relapse stage, sex of patient, the occurrence of acute or Second transplantation chronic GVHD, and the following therapy modalities: CsA withdrawal, IFN-␣, DLT, 2nd BMT. The independence of The conditioning regimen for second transplants consisted of dexamethasone 24 mg/day × 6, melphalan 140 mg/m 2 , covariates with significance levels of less than 5% in univariate analysis was tested by proportional hazards general etoposide (400 mg/m 2 /day × 4), cytosine arabinoside (400 mg/m 2 /day × 4) and cyclophosphamide (60 mg/kg/day × 2) linear model (PHGLM) analyses using forward and backward selection processes. (Dexa-MEAC) in three patients, and cyclophosphamide (60 with an isolated cytogenetic relapse developed a cytopressive prophylaxis or therapy with CsA were initially genetic relapse or hematological relapse 1 and 3.5 years treated by CsA withdrawal. Nine of these patients were in later. One patient who relapsed hematologically developed cytogenetic relapse, one patient had relapsed in a chronic an extramedullary disease recurrence. and 10 patients in an advanced disease phase. At the time GVHD occurred in all patients independent of the type of relapse CsA was administered at a median dose of 126 of response. GVHD involved predominantly the skin with mg (range 75-200) and was withdrawn stepwise within 2 the appearance of a diffuse maculopapular rash. Liver weeks. To control increased cell counts patients with an involvement with GVHD was noted in four of 20 patients, advanced disease recurrence were also treated with chemowhereas gut involvement was not observed. therapy consisting either of hydroxyurea alone or in combiAlmost all patients developed grade I-II acute GVHD nation with thioguanine or cytosine arabinoside. All after CsA withdrawal whether they responded or not, and patients in cytogenetic relapse and the single patient in two patients developed an isolated sicca syndrome. In a chronic phase responded to CsA withdrawal by achieving single patient with an advanced disease stage, grade III a complete hematological and cytogenetic remission. In GVHD with a generalized erythema occurred and all others addition, BCR-ABL transcript negativity was documented developed grades I-II disease. Despite the occurrence of in all but one patient. Five of the nine complete responders GVHD symptoms, a sustained remission was not attained achieved a complete chimeric status according to VNTR-PCR analysis.
in patients with advanced disease recurrence. GVHD occurred within 2 weeks of CsA withdrawal. Table 2 shows with chemotherapy consisting of hydroxyurea, and/or thioguanine or cytosine arabinoside. Only one patient with the data of patients who were treated with CsA withdrawal.
CML in accelerated phase responded to IFN-␣ therapy and achieved hematologic and cytogenetic remission. MoreInterferon alpha therapy over, molecular analyses also demonstrated complete molecular remission after a period of 24 months as detected by Eleven patients who did not receive any immunosuppressants at the time of relapse were treated with IFN-␣ at a negative PCR assay. Neither of the two patients with CML relapse in blast crisis responded to IFN-␣, although in all dose range between 0.5 and 6 × 10 6 IU per day. Seven of these 11 patients had been pretreated with DLT without any patients a cytoreductive effect of IFN-␣ was observed.
With IFN-␣, mild signs of GVHD appeared, and nine of response. No response to pretreatment with DLT was defined either as a disease progression documented by an 11 patients developed a sicca syndrome. GVHD greater than grade I did not occur. One patient in BC had transient increase in leukocyte count or increase in Ph+ chromosomes in cytogenetic analysis, or when no change was seen elevation of liver enzymes probably related to IFN-␣ therapy. Three patients developed a transient severe neutroafter an observation period of at least 3 months since the last DLT infusion.
penia. Table 3 shows the data of patients who were treated with IFN-␣. Two of the 11 study patients had an isolated cytogenetic relapse. Four of the nine patients with hematologic relapses were in chronic phase, while the remaining five patients relapsed in a more advanced phase of CML (three AP, two Donor leukocyte transfusions BC). One patient with a cytogenetic relapse responded to IFN-␣ therapy with a complete remission after 19 months Fourteen patients with relapsed CML were treated with DLT. Two of these 14 patients had been previously treated of therapy. The second patient in cytogenetic relapse has been receiving IFN-␣ therapy for about 6 months and has by CsA withdrawal without any success according to the criteria mentioned above and one other patient was prenot responded yet.
Three of the four patients in CP reached a complete hemtreated with IFN-␣ without any response. Five patients were in CP, and nine in a more advanced disease stage atological response after a median of 7 months (4-12 months), and two of three patients in remission were also (three AP, six BC) at the time of relapse. Between one and seven DLT were transfused weekly (median 3). Only one BCR-ABL negative with a complete chimeric status.
Five patients in an advanced stage of CML were treated patient with CP CML achieved a complete hematological, cytogenetic and molecular remission after seven DLT. for between 3 and 24 months with IFN-␣ in combination Moreover, this patient also had a completely chimeric status IFN-␣. The third patient developed an extramedullary manifestation of CML and died 12 months later. The fourth as demonstrated by VNTR analysis.
Of the four patients in CP who did not respond to DLT, patient, who is classified as a non-responder to DLT, had received a single DLT, because the donor suffered from one underwent a second BMT and another was treated with cardiovascular collapse after the first leukocyte collection, ical relapse and to the second BMT was 32 (range 18-59) so that the administration of a second DLT was not carried months and 62 (range 24-84) months, respectively. Two out and therapy with IFN-␣ was initiated.
patients died as a consequence of grade IV acute GVHD. Only one of the nine patients with a relapse in an One patient in an accelerated phase of CML died 6 months advanced phase responded transiently to DLT by achieving later after a second relapse. Two patients who were transa complete cytogenetic remission. Five months later, after planted in the blastic phase with PBPCs are still in comachieving a cytogenetic remission this patient developed an plete remission at 22 months and 10 months post-transplanextramedullary relapse and died. Three patients died tation. A patient who was retransplanted in a stable phase between 3 and 12 months after DLT. Two patients are alive of CML is 25 months post-2nd BMT, still in complete 8 and 15 months after DLT on treatment with IFN-␣. One remission. This patient only developed GVHD grade I after of the latter achieved complete remission with IFN-␣ therthe 2nd BMT, whereas in the other three patients GVHD apy. Two non-responders received a second transplant.
grade II occurred. One patient who relapsed in an accelerated phase died Thus, three of six patients survived the second transplant from a severe GVHD grade IV within 2 weeks after DLT and achieved a second complete remission. All three from her HLA-mismatched donor. Grades I-II acute patients achieved a complete chimeric status and two of GVHD occurred in six patients. Two patients had transient them remain BCR-ABL negative in all PCR analyses. Table absolute granulocyte counts below 500/mm 3 . Table 4 shows 5 shows data of patients who were treated with a second data of patients who were treated with DLT.
BMT.
Second transplants
Two patients in CP of CML relapse, and four patients in Other therapies an advanced stage of CML relapse underwent a second transplant after failure of IFN-␣, DLT or chemotherapeutic Chemotherapy alone was given to 10 CML patients in hempretreatments. All six patients received transplants from the atological relapse. All patients except one relapsed with an same HLA-identical sibling donor.
advanced disease phase of CML. In no case did a partial GVHD prophylaxis was not given to two patients and or complete hematological response occur. The single was with CsA alone in the remaining four patients. Two patient with stable disease died 79 months after the relapse. patients received peripheral blood progenitor cell (PBPC)
The median survival for patients in advanced phase was 13 transplants, while four patients were transplanted with months with a range of 2-31 months. bone marrow.
Two patients who relapsed cytogenetically 4 and 10 Myeloablative conditioning consisted of melphalan, etomonths post-BMT spontaneously achieved a complete cytoposide, Ara-C and cyclophosphamide (n = 3), or busulfan genetic and molecular remission 3 and 24 months later and cyclophosphamide with or without thiotepa (n = 3).
without any further specific therapy. The median duration from the first BMT to hematolog- Table 5 Response to retransplantation Discussion that at least some of the observed cytogenetic remissions have not been obtained 'spontaneously', but were induced by CsA withdrawal. 3 In this study we examined the outcome of five different therapeutic modalities in 48 patients in whom a relapse of CsA withdrawal was accompanied by the development of acute GVHD in all patients, even in those in whom a CML occurred after allogeneic BMT. Cyclosporin A withdrawal, interferon alpha-2b therapy, donor leukocyte transhematological response was not induced. This observation is consistent with previously published experiences with fusions, second transplants, and chemotherapy alone were used, were studied for their response rates, and were comCsA withdrawal.
12-16
In a study by van Rhee et al, 5 only two of four patients pared with each other.
A strong effect was observed after CsA withdrawal. All had a hematological response after CsA withdrawal. None of these patients attained a complete remission. These nine patients with a cytogenetic relapse, and one patient with a hematological relapse in the CP of CML responded patients, however, had received in vitro or in vivo T celldepleted marrow, and this might have adversely influenced to CsA withdrawal after a median of 53 days and achieved hematological and cytogenetic remissions. In contrast, the allogeneic antileukemic effect associated with CsA withdrawal.
5 patients with advanced CML at the time of relapse responded poorly to CsA withdrawal, in that only one out The mechanisms by which CsA withdrawal may induce or augment antileukemic activity against residual clonoof 10 patients achieved a transient complete cytogenetic remission.
genic CML cells after allogeneic BMT is currently not understood. CsA reduces T cell HLA-DR and interleukinDespite single case reports which have described the remission-inducing effect of CsA withdrawal after post-2 receptor expression (IL-2R), 33, 34 breaks self-tolerance and induces killer cells with specificity against class II MHC transplant relapses, little is known about this procedure. According to these single case reports, the abrupt with-(Ia) antigens both on the host and tumor cells. [33] [34] [35] The withdrawal of CsA may therefore lead to a rebound drawal of CsA can induce remissions not only in patients with CML, but also in patients with ANL and Burkitt's phenomenon with an increase in the number and activity of T cells, 16 an overexpression of surface antigens such as lymphoma.
12-16 It appears likely that the effect of CsA withdrawal has not been adequately considered in all MHC-, DR antigens and IL2R and an increased cytokine release. Some of these mechanisms, which are induced by reports dealing with the treatment of post-transplant relapses of CML and might therefore be underestimated. In CsA withdrawal may thus accelerate an inapparent GVL reaction. The cellular basis of clinical GVL reactions needs one report, for example, 40% of cytogenetic relapses patients were described as achieving spontaneous cytofurther definition, but current evidence points to a role of cytotoxic T cell clones with reactivity against major or genetic remissions. Since 25% of patients had previously undergone CsA withdrawal, it appears justified to speculate minor histocompatibility antigens not shared between donor and recipient. 16 It therefore appears that CsA withdrawal is complete remission to DLT therapy only in one of five patients with CML relapsing in chronic phase, and a transioperative in antigen presentation as well as in the effector phase of the immune response underlying the GVL effect.
ent response in one of eight patients with advanced disease at the time of relapse. One patient with CML relapsing in A slightly higher response rate of post-transplant CML relapse to IFN-␣ was observed in the present study as comadvanced disease, who was partially HLA compatible with her family donor, died from a severe GVHD reaction 1 pared to other published sudies. IFN-␣ induced a stable cytogenetic remission in five of 11 patients (45%). Half of week after the first DLT was given, and was therefore not evaluable for response. Thus, only two of 14 patients these patients had relapsed in advanced stage CML (three AP, two BC), four patients in CP, and the remaining two responded to DLT therapy (14%).
The difference in response rates compared with other patients had a cytogenetic recurrence.
Higano et al 9 described a cytogenetic response to IFNstudies might depend in part on simultaneous or preceding IFN-␣ therapy, which can itself induce a GVL effect or ␣ therapy in six of 18 patients (33%) with a stable disease.
9
Notably lower response rates to therapy with IFN-␣ were which may augment the GVL inducing effect of DLT. We therefore compared the published data on the response rates reported in patients after T cell-depleted BMT. In the study of Arcese et al 3 a complete response rate of 16% in 64 of DLT with reference to the influence of previous IFN-␣ treatment (Tables 7 and 8 ). This analysis revealed signifirelapsed CML patients (24 patients with cytogenetic relapse, 28 CP, eight AP and four BC) was described. This cantly higher response rates in those patients who had been treated with IFN-␣ and DLT for a CML relapse after study group reported an even lower response rate of only 11% with two complete remissions in the 18 patients studunmanipulated BMT as compared to DLT therapy alone. A comparison of the influence of T cell depletion further ied (14 cytogenetic relapse, three CP, one AP) in a previous study. 10 No cytogenetic remissions were found by Hughes suggests that response rates to DLT are significantly higher if DLT were given as a treatment for relapse in patients et al 11 in nine patients who were treated with IFN-␣ for CML relapsing after BMT (three cytogenetic relapse, six who had received a TCD transplant. In contrast, no synergistic effect of IFN-␣ and TCD was detectable in relapsing CP). T cell depletion of the marrow graft might cause a difference in the response rates to IFN-␣. This possible difpatients who had received a TCD transplant (Tables 7  and 8 ). ference is supported by the present meta analysis, in which the response rates of patients after non-TCD marrow trans-T cell depletion is associated with a higher relapse rate, presumably caused by the elimination of immune effector plantation were significantly higher as compared to patients who received IFN-␣ for the treatment of a relapse which cells from the graft, responsible for the GVL effect. By transfusion of allogeneic immune reactive T cells postoccurred after a TCD transplant (Table 6) .
We observed only mild GVHD reactions to IFN-␣. In transplant a strong allogeneic immune reaction accompanied by a 'graft versus leukemia' effect can be prono case was a GVHD reaction of more than grade I observed and severe transient aplasia occurred in two voked, while such reactions have already been operative in patients transplanted with unmanipulated marrow. As a patients. There is limited knowledge regarding the pharmocologic mechanisms by which IFN-␣ induces cytogenetic consequence, it may be anticipated that the GVL effect induced by DLT is much more pronounced in recipients of responses in CML patients. IFN-␣ is capable of enhancing the expression of major (and possibly minor) histocompat-T cell-depleted grafts than in patients who have relapsed after unmanipulated grafts. In the latter patient group, augibility antigens and of activating lymphocytes mediating antigen-specific and nonspecific cytotoxicity. [36] [37] [38] [39] [40] [41] Furthermentation of the GVL effect induced by DLT may therefore be necessary. more, in vitro activities of IFN-␣ on hematopoietic progenitor and marrow stroma cells include growth inhibition, A second transplant with unmanipulated marrow was given to six patients (two CP, two AP, two BC), who did modulation of adhesion molecule expression, and release of growth-regulating cytokines and receptors. [39] [40] [41] [42] not respond to various treatment approaches, including DLT, IFN-␣, and CTX. Two of six patients with advanced The use of donor leukocyte transfusions has been reported to be effective in the treatment of relapsed CML stage disease recurrence were transplanted with allogeneic peripheral blood progenitor cells. patients, with response rates ranging between 30 and 90%. [5] [6] [7] [8] [43] [44] [45] [46] [47] [48] Contrary to other studies, we found a durable Second transplants are associated with a higher risk of Table 6 Influence of T cell-depleted (TCD) or non-TCD bone marrow transplantation on the remission inducing effect of interferon-␣ in CML patients therapy-associated mortality 3, 17 and survival rates of frequencies of minimal residual disease and mixed chimerism in the early post-transplant period and may therefore between 30 and 60% have been described for CML patients at 24 months after a second transplant. Three of six patients support an enhanced antileukemic efficiency. 28 As expected, the use of chemotherapy alone in patients patients survived a median of 16 months post-transplant (range 6-22) and all are free of leukemia by conventional who received no immunomodulatory therapy did not result in cytogenetic remission and this group had a median surcriteria. The causes of death in deceased patients were relapse (n = 1) and GVHD (n = 2). Patients with CML have vival of only 14 months. Two of our study patients with an isolated cytogenetic a better outcome than patients with other leukemias after second transplants, 17 and the results depend to a large relapse achieved a durable remission without further therapy. This phenomenon of spontaneous cytogenetic converextent upon the interval between the first and second trans plant. [17] [18] [19] [20] In the present study, the median interval between sion has been previously described. 3 The retrospective meta analysis including the published the first and second transplant was 62 months, and this might have favorably influenced the outcome in our experience and our own data (Tables 6-8) strongly suggests that the efficacy of immunomodulating therapeutic patients.
Whether PBPCTs, which were performed in two of three approaches depends upon whether the graft was T cell depleted or not. It further supports the view that the hiersurviving patients, have advantages over second BMTs remains to be determined. Preliminary experience from our archy of immunomodulatory measures may further depend upon the type of transplant and the time of relapse. For institution, indicates that PBPCTs are associated with lower result in a 25% remission rate. 2462-2465. In considering the published experience, we propose that 
